Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 11, 2010, Pages 2958-2968

  Steinbrecher, Astrid ^a   Méplan, Catherine ^b   Hesketh, John ^b   Schomburg, Lutz ^c   Endermann, Tobias ^c   Jansen, Eugène ^d   Åkesson, Björn ^e   Rohrmann, Sabine ^a   Linseisen, Jakob ^a,f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e LUND UNIVERSITY   (Sweden)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; SELENIUM; SELENOPROTEIN P;

ADULT; ALLELE; ARTICLE; BLOOD LEVEL; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; EUROPE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; SELENOPROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78549266895     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0364     Document Type: Article

References (51)

1. Gromadzinska J, Reszka E, Bruzelius K, Wasowicz W, Akesson B. Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur J Nutr 2008;47 Suppl 2:29-50.
2. Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science 2003;300:1439-43.
3. Bellinger FP, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009;422:11-22.
4. Nadiminty N, Gao AC. Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res 2008;52:1247-60.
5. Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res 2008;52:1261-72.
6. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4.
7. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
8. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9.
9. Rayman MP. The importance of selenium to human health. Lancet 2000;356:233-41.
10. Meplan C, Crosley LK, Nicol F, et al. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J 2007;21:3063-74.
11. Meplan C, Crosley LK, Nicol F, et al. Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4 gene: interaction with sex. Am J Clin Nutr 2008;87:1019-27.
12. Peters U, Chatterjee N, Hayes RB, et al. Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2008;17:1144-54.
13. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, Rayman MP. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008;68:10171-7.
14. Kumaraswamy E, Malykh A, Korotkov KV, et al. Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biol Chem 2000;275:35540-7.
15. Ravn-Haren G, Olsen A, Tjonneland A, et al. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 2006;27:820-5.
16. Jablonska E, Gromadzinska J, Sobala W, Reszka E, Wasowicz W. Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Nutr 2008;47:47-54.
17. Arsova-Sarafinovska Z, Matevska N, Eken A, et al. Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int Urol Nephrol 2009;41:63-70.
18. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:205-15.
19. Kroke A, Bergmann MM, Lotze G, Jeckel A, Klipstein-Grobusch K, Boeing H. Measures of quality control in the German component of the EPIC study. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:216-24.
20. Pearce N. Incidence density matching with a simple SAS computer program. Int J Epidemiol 1989;18:981-4.
21. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-69.
22. Sieniawska CE, Mensikov R, Delves HT. Determination of total selenium in serum, whole blood and erythrocytes by ICP-MS. J Anal Atomic Spectrom 1999;14:109-12.
23. Hollenbach B, Morgenthaler NG, Struck J, et al. New assay for the measurement of selenoprotein P as a sepsis biomarker from serum. J Trace Elem Med Biol 2008;22:24-32.
24. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 2006;42:2463-71.
25. Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev 2006;15:804-10.
26. Duffield AJ, Thomson CD, Hill KE, Williams S. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 1999;70:896-903.
27. Marchaluk E, Persson-Moschos M, Thorling EB, Akesson B. Variation in selenoprotein P concentration in serum from different European regions. Eur J Clin Nutr 1995;49:42-8.
28. Hagmar L, Persson-Moschos M, Akesson B, Schutz A. Plasma levels of selenium, selenoprotein P and glutathione peroxidase and their correlations to fish intake and serum levels of thyrotropin and thyroid hormones: a study on Latvian fish consumers. Eur J Clin Nutr 1998;52:796-800.
29. Rasmussen LB, Hollenbach B, Laurberg P, et al. Serum selenium and selenoprotein P status in adult Danes - 8-year followup. J Trace Elem Med Biol 2009;23:265-71.
30. Nomura AM, Lee J, Stemmermann GN, Combs GF, Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7.
31. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8.
32. van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003;12:866-71.
33. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between α-tocopherol, γ-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23.
34. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696-703.
35. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 1990;82:864-8.
36. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1069-76.
37. Allen NE, Appleby PN, Roddam AW, et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2008;88:1567-75.
38. Peters U, Foster CB, Chatterjee N, et al. Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr 2007;85:209-17.
39. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
40. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
41. Hesketh J. Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics. Annu Rev Nutr 2008;28:157-77.
42. Schomburg L, Schweizer U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim Biophys Acta 2009;1790:1453-62.
43. Jablonska E, Gromadzinska J, Reszka E, et al. Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans. Eur J Nutr 2009.
44. Forsberg L, de FU, Marklund SL, Andersson PM, Stegmayr B, Morgenstern R. Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1. Blood Cells Mol Dis 2000;26:423-6.
45. Hu YJ, Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 2003;63:3347-51.
46. Burk RF, Hill KE. Selenoprotein P-Expression, functions, and roles in mammals. Biochim Biophys Acta 2009;1790:1441-7.
47. Meplan C, Nicol F, Burtle BT, et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 2009;11:2631-40.
48. Lichtenstein P, de FU, Floderus B, Svartengren M, Svedberg P, Pedersen NL. The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med 2002;252:184-205.
49. Ioannidis JP, Castaldi P, Evangelou E. A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J Natl Cancer Inst 2010;102:846-58.
50. Penney KL, Schumacher FR, Li H, et al. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila Pa) 2010;3:604-10.
51. Meyer HA, Hollenbach B, Stephan C, et al. Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2009;18:2386-90.